Press Releases

For press releases issued prior to June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc., please visit Innoviva, Inc.

Date Title  
08/08/17
Meaningful Clinical Readouts Underpin Progress in Key Programs Additional Milestones Anticipated in Remainder of 2017 and 2018 DUBLIN , Aug. 8, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today reported financial results for the second
08/08/17
Evidence of Localized Target Engagement after Four Weeks of Treatment Minimal Systemic Exposure No Evidence of Systemic Immunosuppression or Infections Company Plans to Progress TD-1473 into Induction and Maintenance Study in 2018 DUBLIN , Aug. 8, 2017 /PRNewswire/ --  Theravance Biopharma, Inc.
08/02/17
Improvements in Symptoms and Normalized Gastric Emptying Demonstrated in both Diabetic and Idiopathic Gastroparesis Patients DUBLIN, Ireland , Aug. 2, 2017 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today announced positive results from a
08/01/17
DUBLIN , Aug. 1, 2017 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today announced that it will release financial results for the period ended June 30, 2017 after market close on Tuesday, August 8, 2017 .
07/31/17
Experienced Life Science Leader with Track Record of Business Development and Portfolio Management Successes DUBLIN , July 31, 2017 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today announced the appointment of Shehnaaz Suliman , MD, to the
07/19/17
These Data, Combined with Positive Results from Two Phase 3 Efficacy Studies, Support NDA Filing Planned for Fourth Quarter of 2017 DUBLIN, IRELAND, Hertfordshire, england and pittsburgh – July 19, 2017 – Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V.
06/05/17

VIBATIV (telavancin) Demonstrates Greater in vitro Activity Compared to Competitor Antibiotics Against Range of Challenging Infection Types

05/23/17

Presentations Review Detailed Efficacy and Safety Data from Two Replicate Pivotal Phase 3 Studies; Report Prevalence of COPD Patients with Low Peak Inspiratory Flow Rate in Ongoing 12-Month Phase 3 Safety Trial

05/17/17

Presentations Will Include Detailed Efficacy and Safety Data from Two Replicate Pivotal Phase 3 Studies

05/09/17

Key Program Milestones Anticipated in Remainder of 2017 and 2018